|PUBLICATIONS (Ranked by impact factor of the journal)|
Molecular and Transcriptional Basis of CD4+ T Cell Dysfunction during Chronic Infection|
Although CD4+ T cells are critical for controlling viral load during chronic viral infections, less is known about their differentiation and transcriptional program. Scientists defined the phenotypic, functional, and molecular profiles of exhausted CD4+ T cells. [Immunity]
Interferon Lambda Alleles Predict Innate Antiviral Immune Responses and Hepatitis C Virus Permissiveness
Using a laser capture microdissection-driven unbiased systems virology approach, scientists isolated and transcriptionally profiled Hepatitis C virus (HCV)-infected and adjacent primary human hepatocytes approaching single-cell resolution. An innate antiviral immune signature dominated the transcriptional response but differed in magnitude and diversity between HCV-infected and adjacent cells. [Cell Host Microbe]
Full Article |
Toll-Like Receptor-Deficient Mice Reveal How Innate Immune Signaling Influences Salmonella Virulence Strategies
Researchers evaluated Salmonella enterica serovar Typhimurium (ST) virulence in mice lacking all toll-like receptor (TLR) function. When delivered systemically to TLR-deficient mice, ST do not require Salmonella pathogenicity island 2 and maintain virulence by replicating extracellularly. [Cell Host Microbe]
Quantitative and Qualitative Deficits in Neonatal Lung-Migratory Dendritic Cells Impact the Generation of the CD8+ T Cell Response
Researchers compared the responses of two dendritic cell (DC) populations in neonatal and adult mice following intranasal infection with respiratory syncytial virus. The response in neonates was dominated by functionally-limited CD103+ DCs, while CD11b+ DCs were diminished in both number and function compared to adults. [PLoS Pathog]
Full Article |
Dendritic Cells Coordinate Innate Immunity via MyD88 Signaling to Control Listeria monocytogenes Infection
Researchers showed that myeloid differentiation factor 88 (MyD88) signaling in dendritic cells is sufficient to mediate the protective innate response, including the production of proinflammatory cytokines, neutrophil infiltration, bacterial clearance, and full protection from lethal infection. [Cell Rep]
Full Article |
Human Protein Staufen-2 Promotes HIV-1 Proliferation by Positively Regulating RNA Export Activity of Viral Protein Rev
Researchers established that human Staufen-2, a host factor which is up-regulated upon HIV-1 infection, interacts with HIV-1 Rev, thereby promoting its RNA export activity and progeny virus formation. [Retrovirology]
HIV-2 Vpx Interacts with IRF5 and Inhibits Its Function
Researchers demonstrated that HIV-2 Vpx interacts with interferon regulatory factor (IRF)5, and Vpx inhibits IRF5-mediated transactivation. Expression of Vpx in THP-1 cells reduced mRNA levels and protein production of Toll-like receptor dependent IL6, IL12p40 and TNFa induced by lipopolysaccharide, R848 and ODN2216. [J Biol Chem]
Differential Blood and Mucosal Immune Responses against an HIV-1 Vaccine Administered via Inguinal or Deltoid Injection
Researchers performed a randomized, double-blinded, placebo-controlled Phase I trial in HIV-1-uninfected volunteers, using the recombinant Canarypox vaccine vCP205 delivered by different routes. HIV-1-specific CD8+ T lymphocytes were observed in 7/12 vaccinees, and blood and gut targeting were distinct. [PLoS One]
Toll-Like Receptor 3 Signaling Up-Regulates Expression of the HIV Co-Receptor G-Protein Coupled Receptor 15 on Human CD4+ T Cells
Scientists showed that GPR15 expression in CD4+ T cells is markedly up-regulated in some HIV-1 infected individuals compared to the rest of the infected patients and to healthy controls. [PLoS One]
Win a $25 Amazon Gift Card!
Connexon Creative is evaluating reader interest in a new social media platform. Fill out this quick survey for your chance to win 1 of 4 $25 gift cards! Take survey here
|Don’t forget to subscribe to our sister publications: Human Immunology News
and Immune Regulation News!|
Structural Insights on the Role of Antibodies in HIV-1 Vaccine and Therapy|
Despite 30 years of effort, there is no effective vaccine for HIV-1. However, antibodies can prevent HIV-1 infection in humanized mice and macaques when passively transferred. New single-cell-based methods have uncovered many broad and potent donor-derived antibodies, and structural studies have revealed the molecular bases for their activities. [Cell]
Innate Resistance against Toxoplasma gondii: An Evolutionary Tale of Mice, Cats, and Men
Recent studies have revealed remarkable species specificity of the Toll-like receptors (TLRs) TLR11 and TLR12 and the immunity-related GTPase proteins that are essential elements for detection and immune control of Toxoplasma gondii in mice, but not in humans. The biological and evolutionary implications of these findings for the T. gondii host-pathogen relationship and for human disease are discussed. [Cell Host Microbe]
A Neglected Epidemic: Fungal Infections in HIV/AIDS
The authors summarize the current state of the-art in AIDS-related mycoses, and the key action points required to improve outcomes from these devastating infections. [Trends Microbiol]
Visit our reviews page to see a complete list of reviews in the infectious disease research field.
Soligenix Announces $300,000 NIAID SBIR Grant Award Supporting Further Evaluation of SGX943 as a Treatment for Melioidosis|
Soligenix, Inc. announced that the National Institute of Allergy and Infectious Diseases (NIAID) has awarded Soligenix a Small Business Innovation Research (SBIR) grant to support further preclinical development of SGX943 as a treatment for melioidosis. [Soligenix, Inc.]
Phase I Clinical Trial Begins for Malaria Vaccine Candidate Based on iBio’s Proprietary Technology
iBio, Inc. reported the initiation of a Phase I human safety and immunogenicity clinical study of a transmission-blocking malaria vaccine candidate. [iBio, Inc.]
CytoDyn Submits Protocol to FDA for Phase IIb Clinical Study of PRO 140 for Treatment Substitution in Patients with HIV
CytoDyn Inc. announced that the company has submitted a Phase IIb clinical trial protocol, for its lead product candidate, PRO 140, to the U.S. Food and Drug Administration (FDA) for treatment substitution in patients with HIV. PRO 140 is a humanized monoclonal antibody directed against CCR5, a molecular portal that HIV uses to enter cells, and belongs to a class of HIV therapies known as entry inhibitors that block HIV from entering into and infecting certain cells. [CytoDyn Inc.]
From our sponsor: Learn how ex vivo models drive progress in HIV research. Read the research profiles.
Have we missed an important article or publication in Immunology of Infectious Disease News?
Click here to submit!
Comments or Suggestions? Submit your feedback here.